ExLibris header image
SFX Logo
Title: Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
Source:

Blood [0006-4971] Goicoechea, Ibai yr:2020


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Mina, R. "Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives." Journal of Clinical Medicine (2020). Link to SFX for this item
2. Munshi, Nikhil C. "A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma." Blood Advances 4.23 (2020): 5988-5999. Link to Full Text for this item Link to SFX for this item
3. Diamond, Benjamin T. "Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity." Blood reviews (2021): 100732-100732. Link to SFX for this item
4. Rajkumar, S V. "Multiple myeloma: 2022 update on diagnosis, risk stratification, and management." American journal of hematology. 97.8: 1086-1107. Link to SFX for this item
5. Kriegsmann, K. "Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment." Cancers 12.8 (2020): 2322-15. Link to Full Text for this item Link to SFX for this item
6. Kostopoulos, Ioannis V. "Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches." Frontiers in oncology (2020): 860-860. Link to Full Text for this item Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.